V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10460649 | 10042188 | 1.76 | 99.5 | Curative (C) | 2019-06-03 | 2019-06-20 | null | N | null | CAPECITABINE + RT | 100760449 |
| 10460666 | 10042189 | 1.89 | 81 | Neo-adjuvant (N) | null | 2021-02-05 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | null | null | DOXORUBICIN + OLARATUMAB | 101298396 |
| 10460790 | 10042191 | 1.68 | 60 | null | 2020-01-09 | 2020-01-09 | BLEOMYCIN | 02 | null | AFATINIB | 100490365 |
| 10461081 | 10042193 | 1.68 | 84 | null | 2017-10-07 | 2017-10-14 | CAPECITABINE + CARBOPLATIN | 02 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101644565 |
| 10461136 | 10042194 | 1.72 | 46.5 | null | 2019-10-12 | 2019-10-31 | FEC + DOCETAXEL + TRASTUZUMAB | 02 | null | ATEZOLIZUMAB | 101235793 |
| 10461281 | 10042195 | 1.73 | 52.5 | Curative (C) | 2018-12-23 | 2019-01-09 | ECX | 2 | null | CABAZITAXEL | 100530210 |
| 10461518 | 10042197 | 1.67 | null | Disease modification (D) | 2021-05-02 | 2021-05-06 | null | 2 | N | CARBOPLATIN + PACLITAXEL + PEMBROLIZUMAB | 100640722 |
| 10461533 | 10042198 | null | null | 03 | 2019-10-15 | 2019-12-10 | AML 19 TRIAL | 02 | null | SCALOP-2 TRIAL | 100684452 |
| 10461703 | 10042200 | 1.78 | 76.9 | null | 2022-03-19 | 2022-03-21 | Carboplatin + Liposomal Doxorubicin | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100345423 |
| 10461875 | 10042203 | 1.6 | 71.1 | 03 | 2016-08-12 | 2016-08-19 | Radium 223 | 02 | N | LETROZOLE + PALBOCICLIB | 101721378 |
| 10462117 | 10042205 | 1.76 | 87.8 | null | 2019-09-07 | 2019-09-12 | FLUOROURACIL + OXALIPLATIN | 02 | null | BORTEZOMIB + PANOBINOSTAT | 101325522 |
| 10462188 | 10042206 | 1.73 | 86.6 | 03 | 2019-04-16 | 2019-04-16 | CHLORAMBUCIL + OFATUMUMAB | null | N | VINORELBINE | 100599755 |
| 10462235 | 10042207 | null | 91 | Curative (C) | 2020-06-02 | 2020-06-17 | EC + DOCETAXEL | N | N | IRINOTECAN + MDG | 100017277 |
| 10462369 | 10042209 | 1.63 | 88.8 | Adjuvant (A) | 2019-08-06 | 2019-08-07 | Epirubicin intravesical | 02 | N | IRINOTECAN + MDG | 100965868 |
| 10462518 | 10042210 | 1.73 | null | Palliative (P) | 2018-09-06 | 2018-09-06 | CAPECITABINE + CARBOPLATIN | 02 | N | GEMCARBO | 101519421 |
| 10462633 | 10042212 | 1.68 | null | Adjuvant (A) | 2019-04-06 | 2019-04-17 | FEC + DOCETAXEL + TRASTUZUMAB | 99 | N | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 100657905 |
| 10462696 | 10042213 | 1.7 | 84 | 03 | 2019-02-28 | 2019-03-07 | Melphalan IV High dose | 02 | null | CABAZITAXEL | 101412645 |
| 10462918 | 10042216 | 1.76 | 78.5 | 03 | 2018-04-29 | 2018-05-03 | FEC | 02 | N | CISPLATIN + RT | 100188063 |
| 10463030 | 10042218 | 1.68 | 91 | null | 2018-01-23 | 2019-09-28 | R-GDP | 02 | null | PERTUZUMAB + TRASTUZUMAB | 100462080 |
| 10463139 | 10042220 | 1.8 | 57.3 | 03 | 2017-09-29 | 2017-10-27 | BLEOMYCIN | 02 | N | DA | 100821151 |
| 10463151 | 10042221 | 1.76 | null | Palliative (P) | 2018-09-07 | 2018-09-13 | BENDAMUSTINE + GEMCITABINE + VINORELBINE | 02 | N | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 100188995 |
| 10463235 | 10042222 | 1.75 | 53 | Palliative (P) | null | 2019-07-14 | Fulvestrant + Palbociclib | N | N | FLAIR TRIAL | 100190916 |
| 10463388 | 10042225 | 1.7 | 78 | Curative (C) | 2011-07-03 | 2018-10-06 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | null | N | APALUTAMIDE | 100668308 |
| 10463420 | 10042226 | 1.68 | null | Palliative (P) | 2018-01-02 | 2018-01-16 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | null | GEMCARBO | 101120669 |
| 10463486 | 10042227 | 1.72 | 61.8 | 03 | null | 2017-01-05 | LENALIDOMIDE + RITUXIMAB | 02 | N | BENDAMUSTINE + OFATUMUMAB | 100651563 |
| 10463581 | 10042229 | 1.89 | 79.3 | Palliative (P) | 2018-08-03 | 2018-08-17 | Trastuzumab Subcutaneous | N | null | AFATINIB | 101189011 |
| 10463582 | 10042230 | 1.5 | 98.16 | Curative (C) | 2019-07-10 | 2019-07-12 | Ofatumumab Weekly | N | N | TRASTUZUMAB | 100974210 |
| 10463603 | 10042231 | 0 | 79.4 | Curative (C) | 2018-11-27 | 2018-12-15 | Obinutuzumab + Venetoclax | 02 | Y | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 101362817 |
| 10463797 | 10042233 | 1.85 | 103 | Curative (C) | 2016-07-25 | 2016-08-03 | FCR Oral - Cycle 2 onwards | 02 | Y | SORAFENIB | 100361329 |
| 10463877 | 10042235 | 1.68 | 71 | Neo-adjuvant (N) | 2017-10-11 | 2017-10-12 | null | 02 | N | FLAIR TRIAL | 100227053 |
| 10464201 | 10042239 | 1.74 | 75 | Palliative (P) | 2020-01-18 | 2020-01-18 | Carboplatin + Paclitaxel + Pembrolizumab | 02 | N | LUTETIUM-177 | 100004424 |
| 10464337 | 10042242 | 1.8 | 50.9 | Curative (C) | 2018-05-06 | 2018-05-13 | DABRAFENIB | 02 | null | LOMUSTINE | 101592659 |
| 10464465 | 10042243 | 0 | 80.65 | Palliative (P) | 2014-06-03 | 2014-06-06 | CHOP - 21 days | 02 | N | ANAGRELIDE | 100103226 |
| 10464609 | 10042245 | null | 56.4 | Curative (C) | 2018-11-08 | 2018-11-08 | Apalutamide | 02 | null | EVEROLIMUS | 101842635 |
| 10464627 | 10042246 | 1.63 | 70.9 | Curative (C) | 2018-09-29 | 2018-10-05 | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 02 | N | PACLITAXEL + TRASTUZUMAB | 100879498 |
| 10464820 | 10042248 | 1.63 | 82.9 | Neo-adjuvant (N) | 2019-01-19 | 2019-02-13 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | N | CARBOPLATIN + LIPOSOMAL DOX | 101095479 |
| 10464960 | 10042251 | 1.66 | 76.2 | Disease modification (D) | 2021-01-08 | 2021-01-08 | ABVD | 2 | null | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 101572022 |
| 10465086 | 10042254 | 1.87 | 87.2 | null | 2020-01-03 | 2020-01-07 | CHOP | 02 | null | DASATINIB | 101666902 |
| 10465111 | 10042255 | 1.62 | 0 | null | 2019-09-15 | 2019-10-01 | GEMCITABINE + OXALIPLATIN + RITUXIMAB | 02 | null | VINCRISTINE | 100758195 |
| 10465254 | 10042256 | 1.7 | 121.1 | null | 2019-02-25 | 2019-03-01 | ELOQUENT 2 trial | N | null | CISPLATIN + PEMETREXED | 101770504 |
| 10465324 | 10042258 | 1.71 | 78.2 | 03 | null | 2017-09-26 | Brentuximab Vedotin + Cyclophosphamide + Doxorubicin | 01 | N | CISPLATIN + PEMETREXED | 100043407 |
| 10465351 | 10042259 | 1.55 | 79.3 | Palliative (P) | 2019-12-06 | 2019-12-07 | AML17 TRIAL | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + PERTUZUMAB + TRASTUZUMAB | 100437259 |
| 10465367 | 10042260 | 1.86 | 0 | Curative (C) | 2018-02-27 | 2018-03-20 | PEG INTERFERON | 02 | N | BORTEZOMIB + PANOBINOSTAT | 100076412 |
| 10465380 | 10042261 | 1.58 | 68 | Curative (C) | 2016-02-02 | 2016-02-10 | BLEOMYCIN | 02 | N | GEMCARBO | 101453945 |
| 10465381 | 10042262 | 1.69 | 87 | Curative (C) | 2016-01-26 | 2016-02-01 | CYCLOPHOSPHAMIDE + DOCETAXEL + DOXORUBICIN | 99 | N | CHLVPP | 100096383 |
| 10465398 | 10042263 | 1.63 | 95.8 | 03 | 2018-10-31 | 2018-11-01 | null | null | null | CISPLATIN + RT | 101150734 |
| 10465434 | 10042264 | 1.67 | null | 03 | 2021-06-16 | 2021-07-12 | Binimetinib + Encorafenib | 02 | null | LETROZOLE + PALBOCICLIB | 101803410 |
| 10465593 | 10042266 | 1.72 | 63.45 | Palliative (P) | 2018-03-18 | 2018-04-13 | ECX | 02 | N | BENDAMUSTINE | 100300846 |
| 10465735 | 10042267 | 1.87 | 55.9 | 03 | null | 2020-01-17 | Cyclophos + Dex + Lenalidomide | null | null | CAPECITABINE + RT | 101320526 |
| 10465757 | 10042268 | 1.76 | null | Curative (C) | 2018-12-05 | 2018-12-06 | Tivozanib | 02 | N | CISPLATIN + DOCETAXEL + FLUOROURACIL | 101283390 |